Press Releases – NASDAQ (US) Website

Dec 10, 2018

BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress read more...

Dec 05, 2018

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) read more...

Dec 03, 2018

BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting read more...

Dec 01, 2018

BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting read more...

Nov 28, 2018

Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally read more...

Nov 20, 2018

BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference read more...

Nov 16, 2018

BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology read more...

Nov 15, 2018

Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China read more...

Nov 13, 2018

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) read more...

Nov 07, 2018

BeiGene Reports Third Quarter 2018 Financial Results read more...

Nov 07, 2018

BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma read more...

Nov 05, 2018

BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology read more...

Nov 01, 2018

BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting read more...

Oct 24, 2018

BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma read more...

Oct 22, 2018

BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress read more...

Oct 12, 2018

BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia read more...

Oct 12, 2018

MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies read more...

Oct 10, 2018

BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China read more...

Oct 08, 2018

BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings read more...

Oct 01, 2018

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) read more...